Avita Medical

From Wikipedia, the free encyclopedia
  (Redirected from Clinical Cell Culture)
Jump to: navigation, search
Avita Medical
Public company
Traded as ASXAVH
Industry Regenerative medicine & Respiratory
Founded 1993 (1993)
Founder Fiona Wood
Area served
Key people
Timothy J Rooney, CEO
Products ReCell, ReNovaCell & ReGenerCell. Breath-a-Tech & Funhaler
Slogan Innovation in respiratory and regenerative medicine
Website avitamedical.com

Avita Medical is a clinical and commercial company developing and marketing a range of respiratory and regenerative products. The first regenerative medicine product brought to the market by Avita Medical was ReCell [1] spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in EMEA countries, Canada and Australia.[2] The Avita Medical Respiratory range features Breath-a-Tech and Funhaler both for the effective delivery of asthma treatments. The respiratory range is primarily marketed in Australia.

Company History[edit]

Originally named "Clinical Cell Culture" (ASXC3), the company restructured under the name "Avita Medical" in June 2008.

ReCell, Spray-on Skin[edit]

ReCell is a stand-alone, rapid, autologous cell harvesting, processing and delivery technology that enables clinicians to treat wounds and skin defects using very small samples of the patient’s own cells, accelerating the healing process, eliminating tissue rejection, minimizing scar formation and reintroducing normal pigmentation, vascularization and innervation in the treated wound area. The procedure is performed entirely on site at bedside, utilizes a patented and proprietary ‘spray-on’ application technique, takes approximately 25 min to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.

US Government grant[edit]

In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.[3]

Clinical Programs[edit]

In addition to the US studies for ReCell in burns and scars, ReCell is being studied in a number of small scale post-marketing studies in Europe for venous leg ulcers, Vitiligo, acne scars, scar remodeling, facial rejuvenation (wrinkle revision), treatment of donor graft sites, and hard to heal burn wounds in the elderly.